{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T17:33:46Z","timestamp":1793036026551,"version":"4.5.0"},"reference-count":77,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T00:00:00Z","timestamp":1781481600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceuticals"],"abstract":"<jats:p>Background\/Objectives: The recent approval of the first intranasal calcitonin gene-related peptide receptor antagonist (CGRP-RA), zavegepant, has increased the relevance of this drug class in treating acute migraine. However, introducing an alternative delivery method may result in a different real-world safety profile. Thus, the aim of this study was to assess adverse events (AEs) related to zavegepant through a retrospective pharmacovigilance disproportionality analysis. Methods: We analyzed Individual Case Safety Reports (ICSRs) presenting zavegepant as the suspected drug, submitted to the Food and Drug Administration (FDA) Adverse Event Monitoring System (AEMS) database between 1 January 2023 and 31 December 2025. ICSRs were assessed by using descriptive and disproportionality analyses. Reporting odds ratios (RORs) with 95% confidence intervals (CIs) were used as disproportionality measures. Results were deemed significant if the ROR 95% CI lower bound was &gt;1 and \u22653 ICSRs were available for each drug\u2013event pair. Results: A total of 509 zavegepant-related ICSRs were identified. Most ICSRs involved female patients (n = 353; 69.4%), with a median (quartile 1, Q1\u2013quartile 3, Q3) age of 45 (34\u201356) years. The Medical Dictionary for Regulatory Activities (MedDRA\u00ae) Preferred Terms with the highest RORs were nasal discomfort (n = 62; ROR = 298.85; 95%CI [228.91, 390.17]), rhinalgia (10; 126.09; [67.34, 236.09]), dysgeusia (147; 94.72; [78.19, 114.75]), pharyngeal ulceration (3; 79.20; [25.42, 246.75]), and upper-airway cough syndrome (16; 62.87; [38.19, 103.49]). Conclusions: These results suggest a safety profile for zavegepant consistent with previous knowledge regarding CGRP-RAs. However, nasal and\/or oropharyngeal AEs, plausibly related to intranasal exposure, may affect perceived tolerability and timely use, warranting further investigation.<\/jats:p>","DOI":"10.3390\/ph19060943","type":"journal-article","created":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T00:49:42Z","timestamp":1781743782000},"page":"943","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Safety Profile of Zavegepant in the Treatment of Acute Migraine: Insights from the FDA Adverse Event Monitoring System Database"],"prefix":"10.3390","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8345-8679","authenticated-orcid":false,"given":"Giuseppe","family":"Cicala","sequence":"first","affiliation":[{"name":"Department of Clinical and Experimental Medicine, University of Messina, 98122 Messina, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2019-4696","authenticated-orcid":false,"given":"Maria Antonietta","family":"Barbieri","sequence":"additional","affiliation":[{"name":"Department of Clinical and Experimental Medicine, University of Messina, 98122 Messina, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-1681-1417","authenticated-orcid":false,"given":"Giulia","family":"Russo","sequence":"additional","affiliation":[{"name":"Department of Clinical and Experimental Medicine, University of Messina, 98122 Messina, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0709-5914","authenticated-orcid":false,"given":"Rosella","family":"Ciurleo","sequence":"additional","affiliation":[{"name":"IRCCS Centro Neurolesi \u201cBonino-Pulejo\u201d, Via Palermo S.S. 113, Contrada Casazza, 98124 Messina, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosario","family":"Grugno","sequence":"additional","affiliation":[{"name":"IRCCS Centro Neurolesi \u201cBonino-Pulejo\u201d, Via Palermo S.S. 113, Contrada Casazza, 98124 Messina, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelo","family":"Quartarone","sequence":"additional","affiliation":[{"name":"IRCCS Centro Neurolesi \u201cBonino-Pulejo\u201d, Via Palermo S.S. 113, Contrada Casazza, 98124 Messina, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2509-7449","authenticated-orcid":false,"given":"Edoardo","family":"Spina","sequence":"additional","affiliation":[{"name":"Department of Clinical and Experimental Medicine, University of Messina, 98122 Messina, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,6,15]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1016\/S0140-6736(18)30478-1","article-title":"Migraine","volume":"391","author":"Dodick","year":"2018","journal-title":"Lancet"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1038\/s41582-022-00763-1","article-title":"Global Epidemiology of Migraine and Its Implications for Public Health and Health Policy","volume":"19","author":"Steiner","year":"2023","journal-title":"Nat. Rev. Neurol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"e293","DOI":"10.1097\/j.pain.0000000000002275","article-title":"Global, Regional, and National Burden of Migraine in 204 Countries and Territories, 1990 to 2019","volume":"163","author":"Safiri","year":"2022","journal-title":"Pain"},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Meng, W., and Sui, L. (2024). Headache Disorders: A Persistent Public Health Challenge for the under 50s. Front. Neurol., 15.","DOI":"10.3389\/fneur.2024.1501749"},{"key":"ref_5","first-page":"100130","article-title":"The Structural and Functional Importance of the Thalamus in Migraine Processes with and without Aura. A Literature Review","volume":"24","author":"Semmler","year":"2021","journal-title":"Transl. Res. Anat."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/S0072-9752(10)97033-4","article-title":"Pathophysiology of Cluster Headache and Other Trigeminal Autonomic Cephalalgias","volume":"Volume 97","author":"Waldenlind","year":"2010","journal-title":"Handbook of Clinical Neurology"},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Sharav, Y., and Benoliel, R. (2008). Migraine and Possible Facial Variants (Neurovascular Orofacial Pain). Orofacial Pain and Headache, Mosby.","DOI":"10.1016\/B978-0-7234-3412-2.10009-4"},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Akerman, S., and Goadsby, P.J. (2014). Migraine, Pathophysiology Of. Encyclopedia of the Neurological Sciences, Elsevier. [2nd ed.].","DOI":"10.1016\/B978-0-12-385157-4.01087-3"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.pharmthera.2016.12.005","article-title":"Current and Novel Insights into the Neurophysiology of Migraine and Its Implications for Therapeutics","volume":"172","author":"Akerman","year":"2017","journal-title":"Pharmacol. Ther."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/bs.pbr.2020.05.012","article-title":"A New Era for Migraine: The Role of Calcitonin Gene-Related Peptide in the Trigeminovascular System","volume":"255","author":"Chen","year":"2020","journal-title":"Progress in Brain Research"},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Waite, P.M.E., and Ashwell, K.W.S. (2012). Trigeminal Sensory System. The Human Nervous System, Academic Press.","DOI":"10.1016\/B978-0-12-374236-0.10031-8"},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Welch, K.M.A. (2003). Migraine Mechanisms. Encyclopedia of the Neurological Sciences, Academic Press.","DOI":"10.1016\/B0-12-226870-9\/00197-0"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/S1474-4422(19)30185-1","article-title":"Migraine and the Trigeminovascular System\u201440 Years and Counting","volume":"18","author":"Ashina","year":"2019","journal-title":"Lancet Neurol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"106072","DOI":"10.1016\/j.nbd.2023.106072","article-title":"The Putative Role of Neuroinflammation in the Complex Pathophysiology of Migraine: From Bench to Bedside","volume":"180","author":"Biscetti","year":"2023","journal-title":"Neurobiol. Dis."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Spekker, E., Tanaka, M., Szab\u00f3, \u00c1., and V\u00e9csei, L. (2022). Neurogenic Inflammation: The Participant in Migraine and Recent Advancements in Translational Research. Biomedicines, 10.","DOI":"10.3390\/biomedicines10010076"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"82","DOI":"10.2302\/kjm.60.82","article-title":"Neuropeptide Effects in the Trigeminal System: Pathophysiology and Clinical Relevance in Migraine","volume":"60","author":"Messlinger","year":"2011","journal-title":"Keio J. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1146\/annurev-pharmtox-010814-124701","article-title":"Calcitonin Gene-Related Peptide (CGRP): A New Target for Migraine","volume":"55","author":"Russo","year":"2015","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2693","DOI":"10.1523\/JNEUROSCI.4542-06.2007","article-title":"Sensitization of Calcitonin Gene-Related Peptide Receptors by Receptor Activity-Modifying Protein-1 in the Trigeminal Ganglion","volume":"27","author":"Zhang","year":"2007","journal-title":"J. Neurosci."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1002\/cpdd.345","article-title":"Spotlight on Anti-CGRP Monoclonal Antibodies in Migraine: The Clinical Evidence to Date","volume":"6","author":"Pellesi","year":"2017","journal-title":"Clin. Pharm. Drug Dev."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/s40259-024-00651-8","article-title":"Cardiovascular Adverse Drug Reactions of Anti-Calcitonin Gene-Related Peptide Monoclonal Antibodies for Migraine Prevention: An Analysis from the European Spontaneous Adverse Event Reporting System","volume":"38","author":"Sorbara","year":"2024","journal-title":"BioDrugs"},{"key":"ref_21","unstructured":"(2026, April 01). Food and Drug Administration Full Prescribing Information: EMGALITY, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/761063s010lbl.pdf."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1212\/WNL.0000000000000771","article-title":"Randomized Controlled Trial of the CGRP Receptor Antagonist Telcagepant for Migraine Prevention","volume":"83","author":"Ho","year":"2014","journal-title":"Neurology"},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Rissardo, J.P., and Caprara, A.L.F. (2022). Gepants for Acute and Preventive Migraine Treatment: A Narrative Review. Brain Sci., 12.","DOI":"10.3390\/brainsci12121612"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1007\/s40265-023-01885-6","article-title":"Zavegepant: First Approval","volume":"83","author":"Dhillon","year":"2023","journal-title":"Drugs"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/S1474-4422(22)00517-8","article-title":"Safety, Tolerability, and Efficacy of Zavegepant 10 Mg Nasal Spray for the Acute Treatment of Migraine in the USA: A Phase 3, Double-Blind, Randomised, Placebo-Controlled Multicentre Trial","volume":"22","author":"Lipton","year":"2023","journal-title":"Lancet Neurol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1111\/head.14389","article-title":"Zavegepant Nasal Spray for the Acute Treatment of Migraine: A Phase 2\/3 Double-blind, Randomized, Placebo-controlled, Dose-ranging Trial","volume":"62","author":"Croop","year":"2022","journal-title":"Headache"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s10194-022-01402-2","article-title":"The Global Prevalence of Headache: An Update, with Analysis of the Influences of Methodological Factors on Prevalence Estimates","volume":"23","author":"Stovner","year":"2022","journal-title":"J. Headache Pain"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/978-94-010-9772-7_2","article-title":"Epidemiology in the United Kingdom of Adverse Drug Reactions from Non-Steroidal Anti-Inflammatory Drugs","volume":"Volume 1","author":"Rainsford","year":"1987","journal-title":"Side-Effects of Anti-Inflammatory Drugs"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1007\/s40264-020-00908-5","article-title":"An Evaluation of Postmarketing Reports with an Outcome of Death in the US FDA Adverse Event Reporting System","volume":"43","author":"Marwitz","year":"2020","journal-title":"Drug Saf."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s40801-015-0054-1","article-title":"Adverse Drug Reaction Reporting Pattern in Turkey: Analysis of the National Database in the Context of the First Pharmacovigilance Legislation","volume":"3","author":"Ozcan","year":"2016","journal-title":"Drugs-Real World Outcomes"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1007\/s00228-020-02894-0","article-title":"Quantity Is Not Enough: Completeness of Suspected Adverse Drug Reaction Reports in Spain\u2014Differences between Regional Pharmacovigilance Centres and Pharmaceutical Industry","volume":"76","year":"2020","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"ref_32","unstructured":"(2026, April 08). Food and Drug Administration Full Prescribing Information: ZAVZPRET, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/216386s007lbl.pdf."},{"key":"ref_33","unstructured":"(2026, April 08). Food and Drug Administration Full Prescribing Information: NURTEC ODT, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/212728s028lbl.pdf."},{"key":"ref_34","unstructured":"(2026, April 08). Food and Drug Administration Full Prescribing Information: UBRELVY, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/211765s012lbl.pdf."},{"key":"ref_35","unstructured":"(2026, April 08). Food and Drug Administration Full Prescribing Information: QULIPTA, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/215206s013lbl.pdf."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"12714","DOI":"10.1523\/JNEUROSCI.0100-15.2015","article-title":"Calcitonin Gene-Related Peptide Reduces Taste-Evoked ATP Secretion from Mouse Taste Buds","volume":"35","author":"Huang","year":"2015","journal-title":"J. Neurosci."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1186\/s10194-024-01846-8","article-title":"Comparison of Gepant Effects at Therapeutic Plasma Concentrations: Connecting Pharmacodynamics and Pharmacokinetics","volume":"25","author":"Boucherie","year":"2024","journal-title":"J. Headache Pain"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1208\/s12249-025-03171-y","article-title":"Intranasal Delivery: Formulation Factors and Insights into User Experience","volume":"26","author":"Lobo","year":"2025","journal-title":"AAPS PharmSciTech"},{"key":"ref_39","first-page":"e2021023","article-title":"What Is the Relations between Dysgeusia and Alterations of the Nutritional Status? A Metanarrative Analysis of Integrative Review","volume":"92","author":"Dellafiore","year":"2021","journal-title":"Acta Bio Med. Atenei Parm."},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Ali, M., Hussein, M., Magdy, R., Khamis, A., Al-Azayem, S.A., Othman, A.M., Ahmed, A., and Osama, W. (2022). The Potential Impact of Insulin Resistance and Metabolic Syndrome on Migraine Headache Characteristics. BMC Neurol., 22.","DOI":"10.1186\/s12883-022-02966-x"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"753.e1","DOI":"10.1016\/j.amjmed.2016.02.003","article-title":"The Impact of Aging and Medical Status on Dysgeusia","volume":"129","author":"Syed","year":"2016","journal-title":"Am. J. Med."},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Togni, L., Mascitti, M., Vignini, A., Alia, S., Sartini, D., Barlattani, A., Emanuelli, M., and Santarelli, A. (2021). Treatment-Related Dysgeusia in Oral and Oropharyngeal Cancer: A Comprehensive Review. Nutrients, 13.","DOI":"10.3390\/nu13103325"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1038\/s41582-021-00509-5","article-title":"Diagnosis and Management of Migraine in Ten Steps","volume":"17","author":"Eigenbrodt","year":"2021","journal-title":"Nat. Rev. Neurol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/s10194-018-0865-z","article-title":"Factors Associated with Acute Medication Overuse in People with Migraine: Results from the 2017 Migraine in America Symptoms and Treatment (MAST) Study","volume":"19","author":"Schwedt","year":"2018","journal-title":"J. Headache Pain"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1111\/odi.13199","article-title":"Oral Adverse Effects of Drugs: Taste Disorders","volume":"26","author":"Rademacher","year":"2020","journal-title":"Oral Dis."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"03331024241287224","DOI":"10.1177\/03331024241287224","article-title":"Insights from Triggers and Prodromal Symptoms on How Migraine Attacks Start: The Threshold Hypothesis","volume":"44","author":"Sebastianelli","year":"2024","journal-title":"Cephalalgia"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1111\/head.14484","article-title":"Patient-reported Experiences with Migraine-related Cognitive Symptoms: Results of the MICOAS Qualitative Study","volume":"63","author":"Gerstein","year":"2023","journal-title":"Headache"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1186\/s10194-024-01923-y","article-title":"Migraine and Cognitive Dysfunction: A Narrative Review","volume":"25","author":"Fernandes","year":"2024","journal-title":"J. Headache Pain"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"5697","DOI":"10.1007\/s10072-022-06184-8","article-title":"Gepants\u2014A Long Way to Cure: A Narrative Review","volume":"43","author":"Altamura","year":"2022","journal-title":"Neurol. Sci."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1186\/s10194-023-01676-0","article-title":"Triptan Non-Response in Specialized Headache Care: Cross-Sectional Data from the DMKG Headache Registry","volume":"24","author":"Ruscheweyh","year":"2023","journal-title":"J. Headache Pain"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"3654","DOI":"10.1007\/s00415-023-11706-1","article-title":"Migraine: From Pathophysiology to Treatment","volume":"270","author":"Puledda","year":"2023","journal-title":"J. Neurol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1159\/000448074","article-title":"Distribution of CGRP and TRPV2 in Human Paranasal Sinuses","volume":"203","author":"Sato","year":"2017","journal-title":"Cells Tissues Organs"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.pupt.2017.12.008","article-title":"The Research of the Possible Mechanism and the Treatment for Capsaicin-Induced Cough","volume":"49","author":"Zhang","year":"2018","journal-title":"Pulm. Pharmacol. Ther."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1378\/chest.14-1481","article-title":"Anatomy and Neurophysiology of Cough","volume":"146","author":"Canning","year":"2014","journal-title":"Chest"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1007\/s00455-021-10248-w","article-title":"Oropharyngeal Dysphagia in Older People Is Associated with Reduced Pharyngeal Sensitivity and Low Substance P and CGRP Concentration in Saliva","volume":"37","author":"Tomsen","year":"2022","journal-title":"Dysphagia"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"ii10","DOI":"10.1136\/jnnp.72.suppl_2.ii10","article-title":"Migraine: Diagnosis and management","volume":"72","author":"Elrington","year":"2002","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1046\/j.1526-4610.2001.041006554.x","article-title":"Precipitating and Aggravating Factors of Migraine Versus Tension-type Headache","volume":"41","author":"Spierings","year":"2001","journal-title":"Headache"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1007\/s40005-020-00482-z","article-title":"Factors Influencing Drug Deposition in Thenasal Cavity upon Delivery via Nasal Sprays","volume":"50","author":"Gao","year":"2020","journal-title":"J. Pharm. Investig."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1001\/jama.2021.7939","article-title":"Acute Treatments for Episodic Migraine in Adults: A Systematic Review and Meta-Analysis","volume":"325","author":"VanderPluym","year":"2021","journal-title":"JAMA"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1186\/s10194-024-01913-0","article-title":"Real-World Study of Adverse Events Associated with Triptan Use in Migraine Treatment Based on the U.S. Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS) Database","volume":"25","author":"Liu","year":"2024","journal-title":"J. Headache Pain"},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Puri, S., Kenyon, B.M., and Hamrah, P. (2022). Immunomodulatory Role of Neuropeptides in the Cornea. Biomedicines, 10.","DOI":"10.3390\/biomedicines10081985"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1128\/CVI.00347-09","article-title":"Nasolacrimal Duct Closure Modulates Ocular Mucosal and Systemic CD4+ T-Cell Responses Induced Following Topical Ocular or Intranasal Immunization","volume":"17","author":"Chentoufi","year":"2010","journal-title":"Clin. Vaccine Immunol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"e17454","DOI":"10.7717\/peerj.17454","article-title":"Migraine Eye: Correlation between Migraine and the Retina","volume":"12","author":"Udomwech","year":"2024","journal-title":"PeerJ"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"106704","DOI":"10.1016\/j.buildenv.2020.106704","article-title":"Dry Eye Symptoms in Offices and Deteriorated Work Performance\u2014A Perspective","volume":"172","author":"Wolkoff","year":"2020","journal-title":"Build. Environ."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1186\/s10194-025-02091-3","article-title":"Adverse Events Associated with Gepants: A Pharmacovigilance Analysis Based on the FDA Adverse Event Reporting System","volume":"26","author":"Song","year":"2025","journal-title":"J. Headache Pain"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1111\/head.70049","article-title":"Safety Analysis of Gepants for Migraine Treatment: A Pharmacovigilance Study Using the FDA Adverse Event Reporting System (FAERS) Database","volume":"66","author":"Chen","year":"2026","journal-title":"Headache J. Head Face Pain"},{"key":"ref_67","doi-asserted-by":"crossref","unstructured":"Khaleel, M.A., Khan, A.H., Ghadzi, S.M.S., Adnan, A.S., and Abdallah, Q.M. (2022). A Standardized Dataset of a Spontaneous Adverse Event Reporting System. Healthcare, 10.","DOI":"10.3390\/healthcare10030420"},{"key":"ref_68","doi-asserted-by":"crossref","unstructured":"Cutroneo, P.M., Sartori, D., Tuccori, M., Crisafulli, S., Battini, V., Carnovale, C., Rafaniello, C., Capuano, A., Poluzzi, E., and Moretti, U. (2024). Conducting and Interpreting Disproportionality Analyses Derived from Spontaneous Reporting Systems. Front. Drug Saf. Regul., 3.","DOI":"10.3389\/fdsfr.2023.1323057"},{"key":"ref_69","unstructured":"Food and Drug Administration (2026, April 20). Questions and Answers on FDA\u2019s Adverse Event Reporting System (FAERS), Available online: https:\/\/www.fda.gov\/drugs\/surveillance\/questions-and-answers-fdas-adverse-event-reporting-system-faers."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1002\/cpt.3701","article-title":"FDA Adverse Event Reporting System (FAERS) Essentials: A Guide to Understanding, Applying, and Interpreting Adverse Event Data Reported to FAERS","volume":"118","author":"Potter","year":"2025","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1007\/s40264-025-01560-7","article-title":"An Evaluation of Duplicate Adverse Event Reports Characteristics in the Food and Drug Administration Adverse Event Reporting System","volume":"48","author":"Janiczak","year":"2025","journal-title":"Drug Saf."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1007\/s40264-023-01345-w","article-title":"Challenges and Opportunities in Accessing and Analysing FAERS Data: A Call Towards a Collaborative Approach","volume":"46","author":"Giunchi","year":"2023","journal-title":"Drug Saf."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"109","DOI":"10.2165\/00002018-199920020-00002","article-title":"The Medical Dictionary for Regulatory Activities (MedDRA)","volume":"20","author":"Brown","year":"1999","journal-title":"Drug Saf."},{"key":"ref_74","unstructured":"(2026, April 09). European Medicines Agency Serious Adverse Reaction. Available online: https:\/\/www.ema.europa.eu\/en\/glossary-terms\/serious-adverse-reaction."},{"key":"ref_75","unstructured":"(2026, April 09). Food and Drug Administration What Is a Serious Adverse Event?, Available online: https:\/\/www.fda.gov\/safety\/reporting-serious-problems-fda\/what-serious-adverse-event."},{"key":"ref_76","doi-asserted-by":"crossref","unstructured":"Barbieri, M.A., Russo, G., Sorbara, E.E., Cicala, G., Franchina, T., Santarpia, M., Speranza, D., Spina, E., and Silvestris, N. (2023). Neuropsychiatric Adverse Drug Reactions with Oral Tyrosine Kinase Inhibitors in Metastatic Colorectal Cancer: An Analysis from the FDA Adverse Event Reporting System. Front. Oncol., 13.","DOI":"10.3389\/fonc.2023.1268672"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1007\/s40264-024-01421-9","article-title":"The Reporting of a Disproportionality Analysis for Drug Safety Signal Detection Using Individual Case Safety Reports in PharmacoVigilance (READUS-PV): Development and Statement","volume":"47","author":"Fusaroli","year":"2024","journal-title":"Drug Saf."}],"container-title":["Pharmaceuticals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1424-8247\/19\/6\/943\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T04:24:15Z","timestamp":1782102255000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1424-8247\/19\/6\/943"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,15]]},"references-count":77,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2026,6]]}},"alternative-id":["ph19060943"],"URL":"https:\/\/doi.org\/10.3390\/ph19060943","relation":{},"ISSN":["1424-8247"],"issn-type":[{"value":"1424-8247","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,15]]}}}